3.
晚期胸腺恶性肿瘤姑息化疗方案
Palliative chemotherapy regimens in advanced thymic malignancies
| 研究 | 例数 | 累计周期 | 组织类型 | 研究类型 | 方案 | 药物 | 剂量 | 反应率(%) |
| T,胸腺瘤;TC,胸腺癌。 注:本表已获得版权所有者© 2011 by the International Association for the Study of Lung Cancer复制许可。 | ||||||||
| 单药化疗 | ||||||||
| Bonomi等[20] | 21 | 4 | T/TC | PhaseⅡ | Cisplatin | 50 mg/m2/3wk | 10-62 | |
| Highley等[21] | 15 | 12 | T/TC | Retrospective | Ifosfamide | 1.5 g/m2×5 d/3wk | 46-54 | |
| Loehrer等[34] | 27 | 1 | T/TC | PhaseⅡ | Pemetrexed | 50 mg/m2/3wk | 17 | |
| 多药联合化疗 | ||||||||
| Fornasiero等[2] | 32 | 11 | T | Retrospective | ADOC | Adriamycin | 40 mg/m2/3wk | 85-92 |
| Cisplatin | 50 mg/m2/3wk | |||||||
| Vincristin | 0.6 mg/m2/3wk | |||||||
| Cyclophosphamide | 700 mg/m2/3wk | |||||||
| Loehrer等[10] | 30 | 9 | T/TC | PhaseⅡ | CAP | Cisplatin | 50 mg/m2/3wk | 51 |
| Adriamycin | 50 mg/m2/3wk | |||||||
| Cyclophosphamide | 500 mg/m2/3wk | |||||||
| Giaccone等[11] | 16 | 6 | T | PhaseⅡ | PE | Cisplatin | 60 mg/m2/3wk | 56-60 |
| Etoposide | 120mg/m2×3/wk | |||||||
| Loehrer等[12] | 34 | 2 | T/TC | PhaseⅡ | VIP | Etoposide | 75 mg/m2×4 d/wk | 32 |
| Ifosfamide | 1.2 g/m2×4 d/wk | |||||||
| Cisplatin | 20 mg/m2×4 d/wk | |||||||
| Lemma等[13] | 46 | 7 | T/TC | PhaseⅡ | Carbo-Px | Carboplatin | Area under the curve | 33 |
| Paclitaxel | 5/3wk 225mg/m2/3wk | |||||||